Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT05850234 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05850234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05850234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 20, 2023
Completion date
January 25, 2029
Enrollment
232 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma